Literature DB >> 24749737

Characterization and stability study of polysorbate 20 in therapeutic monoclonal antibody formulation by multidimensional ultrahigh-performance liquid chromatography-charged aerosol detection-mass spectrometry.

Yi Li1, Daniel Hewitt, Yvonne K Lentz, Junyan A Ji, Taylor Y Zhang, Kelly Zhang.   

Abstract

Polysorbate 20 is a nonionic surfactant commonly used in the formulation of therapeutic monoclonal antibodies (mAb) to prevent protein denaturation and aggregation. It is critical to understand the molecular heterogeneity and stability of polysorbate 20 in mAb formulations as polysorbate can gradually degrade in aqueous solution over time by multiple pathways losing surfactant functions and leading to protein aggregation. The molecular heterogeneity of polysorbate and the interference from proteins and the excipient in the formulation matrix make it a challenge to study polysorbate in protein formulations. In this work, the characterization and stability study of polysorbate 20 in the presence of mAb formulation sample matrix is first reported using two-dimensional liquid chromatography (2DLC) coupled with charged aerosol detection (CAD) and mass spectrometry (MS) detection. A mixed-mode column that has both anion-exchange and reversed-phase properties was used in the first dimension to separate protein and polysorbate in the formulation sample, while polysorbate 20 esters were trapped online and then analyzed using an reversed-phase ultrahigh-performance liquid chromatography (RP-UHPLC) column in the second dimension to further separate the ester species. The MS served as the third dimension to further resolve as well as to identify the polysorbate ester subspecies. Another 2DLC method using a cation-exchange column in the first dimension and the same RP-UHPLC method in the second dimension was developed to analyze the degradation products of polysorbate 20. Stability samples of a protein drug product were studied using these two 2DLC-CAD-MS methods to separate, identify, and quantify the multiple ester species in polysorbate 20 and also to monitor the change of their corresponding degradants. We found different polysorbate esters degrade at different rates, and importantly, the degradation rates for some esters are different in the protein formulation compared to a placebo that has no protein. The multidimensional UHPLC-CAD-MS approach provides insights into the heterogeneous stability behaviors of polysorbate 20 subspecies in real-time stability samples of a mAb formulation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24749737     DOI: 10.1021/ac5009628

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  11 in total

Review 1.  Considerations for the Use of Polysorbates in Biopharmaceuticals.

Authors:  Michael T Jones; Hanns-Christian Mahler; Sandeep Yadav; Dilbir Bindra; Vincent Corvari; R Matthew Fesinmeyer; Kapil Gupta; Alexander M Harmon; Kenneth D Hinds; Atanas Koulov; Wei Liu; Kevin Maloney; John Wang; Ping Y Yeh; Satish K Singh
Journal:  Pharm Res       Date:  2018-05-24       Impact factor: 4.200

2.  Degradation Mechanisms of Polysorbate 20 Differentiated by 18O-labeling and Mass Spectrometry.

Authors:  Lin Zhang; Sandeep Yadav; Barthélemy Demeule; Y John Wang; Olivier Mozziconacci; Christian Schӧneich
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

3.  Dual Effect of Histidine on Polysorbate 20 Stability: Mechanistic Studies.

Authors:  Lin Zhang; Sandeep Yadav; Y John Wang; Olivier Mozziconacci; Christian Schӧneich
Journal:  Pharm Res       Date:  2018-01-16       Impact factor: 4.200

4.  A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.

Authors:  Nidhi Doshi; Jamie Giddings; Lin Luis; Arthur Wu; Kyle Ritchie; Wenqiang Liu; Wayman Chan; Rosalynn Taing; Jeff Chu; Alavattam Sreedhara; Aadithya Kannan; Pervina Kei; Ian Shieh; Tobias Graf; Mark Hu
Journal:  Pharm Res       Date:  2021-03-12       Impact factor: 4.200

5.  Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation.

Authors:  Nidhi Doshi; Kyle Ritchie; Tamanna Shobha; Jamie Giddings; Kathrin Gregoritza; Rosalynn Taing; Stephen Rumbelow; Jeff Chu; Anthony Tomlinson; Aadithya Kannan; Miguel Saggu; Si Kai Cai; Victor Nicoulin; Wenqiang Liu; Steve Russell; Lin Luis; Sandeep Yadav
Journal:  Pharm Res       Date:  2021-09-08       Impact factor: 4.200

6.  A Mechanistic Understanding of Monoclonal Antibody Interfacial Protection by Hydrolytically Degraded Polysorbate 20 and 80 under IV Bag Conditions.

Authors:  Aadithya Kannan; Jamie Giddings; Shrenik Mehta; Tiffany Lin; Anthony Tomlinson; Kyle Ritchie; Ian Shieh; Miguel Saggu; Nidhi Doshi
Journal:  Pharm Res       Date:  2022-03-11       Impact factor: 4.200

7.  A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection.

Authors:  Robert E Birdsall; Sean M McCarthy; Marie Claire Janin-Bussat; Michel Perez; Jean-François Haeuw; Weibin Chen; Alain Beck
Journal:  MAbs       Date:  2015-12-14       Impact factor: 5.857

8.  A rapid on-line method for mass spectrometric confirmation of a cysteine-conjugated antibody-drug-conjugate structure using multidimensional chromatography.

Authors:  Robert E Birdsall; Henry Shion; Frank W Kotch; April Xu; Thomas J Porter; Weibin Chen
Journal:  MAbs       Date:  2015-08-25       Impact factor: 5.857

9.  Integrated Clarification and Purification of Monoclonal Antibodies by Membrane Based Separation of Aqueous Two-Phase Systems.

Authors:  Thomas Kruse; Axel Schmidt; Markus Kampmann; Jochen Strube
Journal:  Antibodies (Basel)       Date:  2019-07-02

Review 10.  Photo-Oxidation of Therapeutic Protein Formulations: From Radical Formation to Analytical Techniques.

Authors:  Elena Hipper; Michaela Blech; Dariush Hinderberger; Patrick Garidel; Wolfgang Kaiser
Journal:  Pharmaceutics       Date:  2021-12-28       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.